BiotechTube

Ameluz 10% Topical Gel

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Actinic Keratoses

Conditions

Actinic Keratoses

Trial Timeline

May 3, 2023 → Jun 1, 2025

NCT ID
NCT06745999

About Ameluz 10% Topical Gel

Ameluz 10% Topical Gel is a approved stage product being developed by Biofrontera for Actinic Keratoses. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06745999. Target conditions include Actinic Keratoses.

What happened to similar drugs?

6 of 20 similar drugs in Actinic Keratoses were approved

Approved (6) Terminated (1) Active (14)
✅fluorouracil cream 0.5%SanofiApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Imiquimod + DiclofenacViatrisApproved
✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
✅Tirbanibulin 2.5 mg ointmentAlmirallApproved
✅TirbanibulinAlmirallApproved
🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06745999ApprovedRecruiting

Competing Products

20 competing products in Actinic Keratoses

See all competitors
ProductCompanyStageHype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
29
Investigational Treatment + Active comparatorNovartisPhase 2
35
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
40
FluorouracilSanofiPhase 1/2
32
fluorouracil cream 0.5%SanofiApproved
43
Imiquimod + DiclofenacViatrisApproved
40
Imiquimod 5 % CreamViatrisPhase 2
32
ImiquimodViatrisPre-clinical
23
Aldara (Imiquimod)ViatrisPhase 3
37
Imiquimod + DiclofenacViatrisApproved
40
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
34
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
41
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
34